Evaluation of the absorption from three ibuprofen formulations

Area of Science:

• Pharmacokinetics
• Drug formulation
• Pharmacology

Background:

• Understanding ibuprofen pharmacokinetics is crucial for optimizing pain management.
• Sustained-release formulations aim to provide prolonged therapeutic effects and potentially reduce dosing frequency.
• Comparing different ibuprofen formulations aids in selecting appropriate drug delivery systems.

Purpose of the Study:

• To compare the pharmacokinetic profiles of two sustained-release ibuprofen formulations (300 mg and 400 mg) against a conventional rapid-release 400 mg formulation.
• To assess the absorption rate, peak plasma levels, and bioavailability of different ibuprofen formulations.
• To project plasma concentrations for multiple dosing regimens based on single-dose data.

Main Methods:

• Single-dose pharmacokinetic study involving three ibuprofen formulations: sustained-release 300 mg (A), sustained-release 400 mg (B), and rapid-release 400 mg (C).
• Measurement of plasma ibuprofen concentrations over time to determine pharmacokinetic parameters.
• Statistical analysis to compare absorption rates and bioavailability between formulations.
• Modeling to project plasma concentrations under multiple dosing conditions.

Main Results:

• Sustained-release formulations A and B exhibited significantly slower absorption (p<0.001 and p<0.05) compared to conventional formulation C.
• Mean peak plasma concentrations were lower for A (25.1 µg/ml) and B (31.3 µg/ml) than for C (68.5 µg/ml).
• Bioavailability was comparable across all formulations, with relative bioavailability close to 100% and low inter-subject variability.

Conclusions:

• Sustained-release ibuprofen formulations provide prolonged absorption and lower peak plasma levels compared to conventional tablets.
• The dosage interval concentration ratio was significantly lower for sustained-release formulations, suggesting potential for less frequent dosing.
• These findings support the utility of sustained-release ibuprofen for achieving prolonged therapeutic effects with potentially improved dosing convenience.